Securities code: 300199 securities abbreviation: Hybio Pharmaceutical Co.Ltd(300199) Announcement No.: 2022-021 Hybio Pharmaceutical Co.Ltd(300199)
Suggestive announcement on changes in shareholders' equity of the company
The shareholder Lai Jiansheng guarantees that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Hybio Pharmaceutical Co.Ltd(300199) (hereinafter referred to as the "company" or " Hybio Pharmaceutical Co.Ltd(300199) ") received the short form report on changes in equity issued by the shareholder Lai Jiansheng on January 25, 2022. It was learned that the proportion of shares held by the shareholder Lai Jiansheng in the company had decreased to less than 5%. Now the changes in equity are announced as follows:
1、 Basic information of this equity change
The number of shares held by the information disclosure obligors changed this time is 13000000 shares, with a change ratio of 1.42%. The details are shown in the following table: detailed list of changes in the number of shares held by the information disclosure obligors:
Detailed statement of changes in the number of shares held by information disclosure obligors
Change proportion of number of shares (shares) of shareholder name change on date (%)
January 24, 2022 Lai Jiansheng 13 million 1.42%
2、 Other relevant instructions
1. This change in equity will not affect the normal production and operation activities of the company, and will not lead to changes in the controlling right and actual controller of the company.
2. For details, please refer to the relevant announcements disclosed in the same period on the information disclosure website designated by the China Securities Regulatory Commission on the gem. Please make rational decisions and pay attention to investment risks.
It is hereby announced.
Hybio Pharmaceutical Co.Ltd(300199) board of directors January 26, 2022
